Maria Magdalena Tomasiak-Lozowska

Maria Magdalena Tomasiak-Lozowska

Auto-generated profile, based on publicly available information

Maria Magdalena Tomasiak-Lozowska

Department of Physical Chemistry, Medical University of Bialystok, Bialystok, Poland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in Allergy
Verified
Journal Article
Closed access
PDF file
TBT. Boonpiyathad
T. Boonpiyathad
NMN. Meyer
N. Meyer
MMMarcin Moniuszko
Marcin Moniuszko
MSMilena Sokolowska
Milena Sokolowska
AEAndrzej Eljaszewicz
Andrzej Eljaszewicz
WVW. van de Veen
W. van de Veen

1 March 2009 in Respiratory Medicine
Verified
Journal Article
Closed access
ZZZiemowit Zietkowski
Ziemowit Zietkowski
MTMaria M. Tomasiak-Lozowska
Maria M. Tomasiak-Lozowska
RSRoman Skiepko
Roman Skiepko
Barbara MroczkoBarbara Mroczko
Barbara Mroczko
MSMaciej Szmitkowski
Maciej Szmitkowski
ABAnna Bodzenta-Lukaszyk
Anna Bodzenta-Lukaszyk

26 June 2010 in Respiration
Verified
Journal Article
Open access
PDF file
ZZZiemowit Zietkowski
Ziemowit Zietkowski
RSRoman Skiepko
Roman Skiepko
MTMaria M. Tomasiak-Lozowska
Maria M. Tomasiak-Lozowska
ABAnna Bodzenta-Lukaszyk
Anna Bodzenta-Lukaszyk
Background: Omalizumab is a humanized monoclonal anti-IgE antibody, especially useful for the treatment of severe persistent allergic asthma, inadequately controlled despite regular therapy. Objectives: The aim of the study was to determine the effect of omalizumab treatment on changes in endothelin-1 (ET-1), which plays an important role in the development of airway inflammation and remodeling in exhaled breath condensate (EBC) in patients with severe asthma. Methods: The study was conducted in a group of 19 patients with severe persistent allergic asthma treated with conventional therapy (according to the Global Initiative for Asthma, 2006) and with or without omalizumab (9 vs. 10 patients). Changes in ET-1 in EBC compared with other inflammatory parameters [exhaled nitric oxide – (FENO), blood eosinophil count, and serum eosinophil cationic protein (ECP)] were measured after 16 and 52 weeks of therapy. Results: Omalizumab-treated patients demonstrated a statistically significant decrease in the concentrations of ET-1 in EBC, FENO, serum ECP, and blood eosinophil count and an increase in spirometry parameters compared to patients with conventional therapy. In the group of omalizumab-treated patients, statistically significant correlations between the decrease in ET-1 in EBC and a decrease in FENO, ECP, and blood eosinophil count as well as the increase in forced expiratory volume in 1 s after omalizumab therapy were revealed. Conclusions: Our results confirmed that anti-IgE therapy with omalizumab in patients with severe persistent allergic asthma results in decreased expression of ET-1 in the airways. This could be very important in limiting airway inflammation and bronchial structural changes caused by such treatment in asthmatic patients.

1 September 2018 in Advances in Medical Sciences
Verified
Journal Article
Closed access
MTMaria Magdalena Tomasiak-Łozowska
Maria Magdalena Tomasiak-Łozowska
MKMaciej Klimek
Maciej Klimek
ALAgnieszka Lis
Agnieszka Lis
MMMarcin Moniuszko
Marcin Moniuszko
ABAnna Bodzenta-Łukaszyk
Anna Bodzenta-Łukaszyk

1 August 2008 in Respiratory Medicine
Verified
Journal Article
Closed access
ZZZ. Zietkowski
Z. Zietkowski
MTM.M. Tomasiak
M.M. Tomasiak
RSR. Skiepko
R. Skiepko
ABA. Bodzenta-Lukaszyk
A. Bodzenta-Lukaszyk

31 October 2007 in Respiratory Research
Verified
Journal Article
Open access
PDF file
ZZZiemowit Zietkowski
Ziemowit Zietkowski
RSRoman Skiepko
Roman Skiepko
MTMaria M Tomasiak
Maria M Tomasiak
ABAnna Bodzenta-Lukaszyk
Anna Bodzenta-Lukaszyk
Exercise-induced bronchoconstriction (EIB) is a highly prevalent condition, whose pathophysiology is not well understood. Endothelins are proinflammatory, profibrotic, broncho- and vasoconstrictive peptides which play an important role in the development of airway inflammation and remodeling in asthma. The aim of the study was to evaluate the changes in endothelin-1 levels in exhaled breath condensate following intensive exercise in asthmatic patients.